2 terminated, 1 completed. 2 Phase 2, 1 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Completed 1, Terminated 1 |
| Phase 1 | 1 | Completed 1 |
| Phase 3 | 1 | Terminated 1 |
Follow Mark Stegall: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Janssen Ad26.CoV2.S Vaccine Booster in Kidney Transplant Recipients Janssen Ad26.CoV2.S Vaccine, Reduction in Immunosuppression Medication, Maintenance in Immunosuppression Medication - Kidney Transplant Recipient | Phase 3 | Terminated | Mark Stegall | 468 | 2022-04-11 | 2025-09-15 |
| Impact of Proteasome Inhibition on Anti-Donor HLA Antibody Production After Kidney Transplantation Bortezomib - Disorder of Transplanted Kidney | Phase 2 | Terminated | Mark Stegall | 4 | 2011-12-01 | 2015-10-28 |
| Dosing Regimen of Eculizumab Added to Conventional Treatment in Positive Cross Match Living Donor Kidney Transplant Eculizumab - Kidney Transplant | Phase 1 / Phase 2 | Completed | Mark Stegall | 31 | 2008-03-01 | 2018-06-26 |
COVID-19 (1)
Bortezomib (1) · Maintenance (1) · eculizumab (1)
United States (3)
Mark D Stegall, MD (1) · Mark D. Stegall, M.D. (1)